D
Akero Therapeutics, Inc. AKRO
$48.17 -$0.11-0.23% NASDAQ
Recommendation
Prev Close
$48.28
Volume
633,791
Avg Vol (90D)
1,476,920
Market Cap
$3.86B
Dividend & Yield
--
52-Week Range
$21.34 - $58.40
P/E (TTM)
--
EPS (TTM)
-$3.80
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Best Biotech Stocks to Buy in 2025
5/13/2025 - MarketBeat
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
8/12/2025 - Zacks Investment Research
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS
8/10/2025 - MarketBeat
201,168 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Vivo Capital LLC
8/9/2025 - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of Stock
8/9/2025 - Ticker Report
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from Analysts
8/9/2025 - MarketBeat
Decoding Akero Therapeutics Inc (AKRO): A Strategic SWOT Insight
8/9/2025 - GuruFocus
Akero Therapeutics Advances in MASH Treatment Development
8/9/2025 - TipRanks Financial Blog
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $616,250.00 in Stock
8/8/2025 - MarketBeat
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
8/8/2025 - GuruFocus
Akero (AKRO) Q2 Loss Narrows 6%
8/8/2025 - Fool.com Headlines
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update ...
8/8/2025 - GuruFocus
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
8/8/2025 - Globe Newswire
Jefferies Financial Group Inc. Invests $324,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
8/8/2025 - Ticker Report
Akero Therapeutics (AKRO, $50.45) entered Downtrend as Momentum indicator drops below 0 level on Aug 07, 2025
8/8/2025 - Tickeron - Stocks
Akero Therapeutics (AKRO, $52.79) price moved above its 50-day Moving Average on August 06, 2025
8/7/2025 - Tickeron - Technical Analysis
Akero Therapeutics (AKRO, $52.79) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 6, 2025
8/7/2025 - Tickeron - Technical Analysis
Akero Therapeutics (AKRO, $52.79) entered Uptrend as Momentum indicator ascends above 0 level on Aug 06, 2025
8/7/2025 - Tickeron - Technical Analysis
Noteworthy Wednesday Option Activity: AKRO, CELH, VRNT
8/6/2025 - Stock Options Channel
Video: Why Akero Therapeutics Is Trading Higher Today
8/6/2025 - The Fly
Akero Therapeutics (AKRO, $49.56) Stochastic Oscillator left the oversold zone on August 05, 2025
8/6/2025 - Tickeron - Stocks
Akero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at TD Cowen
8/5/2025 - MarketBeat
Analyst Ritu Baral Initiates Coverage on Akero Therapeutics (AKRO) with 'Buy' Rating AKRO ...
8/4/2025 - GuruFocus
Akero Therapeutics (AKRO) Receives Buy Rating from TD Cowen
8/4/2025 - GuruFocus
3 Mid-Caps Worth Watching Closely in March 
2/28/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$321.46M
EBIT (TTM)
-$321.48M
Net Income (TTM)
-$283.96M
Balance Sheet
Total Assets (Q)
$1.11B
Total Debt (Q)
$36.41M
Total Liabilities (Q)
$83.33M
Book Value Per Share (Q)
$12.84
Cash Flow
Cash from Operations (TTM)
-$253.42M
Cash from Investing (TTM)
-$314.50M
Cash from Financing (TTM)
$478.02M
Net Change in Cash (TTM)
-$89.91M
Filings
Filing Date
Friday, August 8, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.18
7-Day Total Return
-0.43%
30-Day Total Return
-9.75%
60-Day Total Return
20.52%
90-Day Total Return
14.80%
Year to Date Total Return
71.51%
1-Year Total Return
99.09%
2-Year Total Return
1.69%
3-Year Total Return
262.11%
5-Year Total Return
39.76%
52-week Low
Jan 14, 2025 - $21.34
52-week High
Jan 27, 2025 - $58.40
Valuation
Market Cap
$3.86B - Mid Cap
Enterprise Value
$2.81B
Price/Sales (TTM)
--
Price/Book (Q)
3.76
Dividends and Shares
Shares Outstanding
81.72
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
akerotx.com
Phone Number
650 487 6488
Address
601 Gateway Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an... more
NASDAQ 08/12/2025 3:51PM Eastern Quotes delayed